1429182-99-9

Upstream product

• 17016-83-0 (4S)-4-isopropyl-1,3-oxazolidin-2-one 
• 1429181-06-5 (S)-3-(2-fluoropyrimidin-4-yl)-4-isopropyloxazolidin-2-one 
• 1429183-03-8 {4-[(1S)-1-aminoethyl]phenyl}methanol hydrochloride 

Downstream Products

• 1429182-87-5 (S)-3-(2-((S)-1-(4-(chloromethyl)phenyl)ethylamino)pyrimidin-4-yl)-4-isopropyloxazolidin-2-one 
• 1429176-55-5 (4S)-4-isopropyl-3-(2-((⁽¹⁾-1-(4-((5-methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)methyl)phenyl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one 
• 1429176-50-0 (S)-3-(2-(((S)-1-(4-((3,3-dimethylpiperazin-1-yl)methyl)phenyl)ethyl)amino)pyrimidin-4-yl)-4-isopropyloxazolidin-2-one 
• 1429181-92-9 tert-butyl 4-(4-((S)-1-(4-((S)-4-isopropyl-2-oxooxazolidin-3-yl)pyrimidin-2-ylamino)ethyl)benzyl)-2,2-dimethylpiperazine-1-carboxylate 
• 1429182-96-6 4-((S)-1-(4-((S)-4-isopropyl-2-oxooxazolidin-3-yl)pyrimidin-2-ylamino)ethyl)benzaldehyde 

Relevant academic research and scientific papers

3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH

The invention is directed to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1-R6 are defined herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.